June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
TMP778 Inhibits Induction of Experimental Autoimmune Uveitis and related immune responses
Author Affiliations & Notes
  • Samuel Hinshaw
    National Eye Institute, NIH, Bethesda, MD
  • Wambul (Sylvia) Wambul Wandu
    National Eye Institute, NIH, Bethesda, MD
  • Guangpu Shi
    National Eye Institute, NIH, Bethesda, MD
  • Jianfei Yang
    Tempero Pharmaceuticals, GSK, Boston, MA
  • Igal Gery
    National Eye Institute, NIH, Bethesda, MD
  • Footnotes
    Commercial Relationships Samuel Hinshaw, None; Wambul (Sylvia) Wandu, None; Guangpu Shi, None; Jianfei Yang, Tempero Pharmaceuticals, GlaxoSmithKline (E); Igal Gery, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 851. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samuel Hinshaw, Wambul (Sylvia) Wambul Wandu, Guangpu Shi, Jianfei Yang, Igal Gery; TMP778 Inhibits Induction of Experimental Autoimmune Uveitis and related immune responses. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):851.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: TMP778, an inverse agonist of RORγt, was recently demonstrated to inhibit induction of experimental autoimmune disease (Xiao, et al., Immunity, 2014). Here, we determined the immunosuppressive property of TMP778 on the development of experimental autoimmune uveitis (EAU) and related immune responses.

Methods: Female B10.A mice immunized with an emulsion of interphotoreceptor retinoid-binding protein (IRBP) in complete Freund’s adjuvant (CFA) were treated twice daily with TMP778 (provided by Tempero Pharmaceuticals) by subcutaneous injection. Pathological changes in the eyes were determined by fundoscopy, while spleen cells were tested in vitro for cytokine production in response to IRBP. Separately, splenocytes from mice immunized with IRBP were cultured with TMP778 to test its inhibitory effect on the response to IRBP by cytokine release.

Results: Fundoscopic analysis of the eyes showed that treatment of mice with TMP778 significantly inhibited the development of EAU (p ≤ 0.01). Furthermore, splenocytes from mice treated with TMP778 produced significantly less IFN-γ (p ≤ 0.001) and IL-17 (p ≤ 0.01) in response to IRBP than their controls. When added to cultures of splenocytes sensitized against IRBP, TMP778 strongly inhibited the release of IL-17. Additional data of ongoing studies are to be reported at the meeting.

Conclusions: Treatment of mice with TMP778 inhibits the development of EAU and cellular immune responses to IRBP. TMP778 and other inverse agonists of RORγt are a promising class of compounds for inhibition of immune-mediated disease.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.